These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 15811208

  • 1. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
    Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR.
    Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
    [Abstract] [Full Text] [Related]

  • 2. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 3. Beyond daily dosing: clinical experience.
    Cooper C.
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY.
    Curr Pharm Des; 2005 Apr; 11(28):3711-28. PubMed ID: 16305506
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.
    Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.